Tag:
PCSK9 drugs
Latest Headlines
Latest Headlines
Sanofi's move to acquire Regeneron shares triggers market buzz
Regeneron Pharmaceuticals notified investors today that its longtime partner Sanofi is moving to snap up a big chunk of its stock.
UPDATED: Amgen highlights late-stage pipeline, biosimilars in growth plan
The Thousand Oaks, CA-based biotech powerhouse made an unexpected move in December to buy the pioneering genomics company deCODE for $415 million. Today R&D chief Dr. Sean Harper further explained how the capabilities of the company fit within the broader strategy at Amgen to be more discerning about which research programs to pursue.
Alnylam licenses away hot PCSK9 prospect in 'small' $205M deal
The Medicines Co. has bought into one of the most exciting cardio drug targets in biotech, licensing a PCSK9 candidate from Alnylam Pharmaceuticals for $25 million upfront and up to $180 million in milestones, the companies said today.
PCSK9 rivals Amgen and Pfizer angle for AHA spotlight with promising data
Those hot PCSK9 bad cholesterol drugs elbowed their way to center ring at the American Heart Association meeting, with Amgen grabbing the spotlight with a fresh batch of positive midstage data on their program for AMG 145.
Amgen, Pfizer eye blockbuster purse in next leg of PCSK9 cholesterol drug race
The monoclonal antibody , AMG-145, has the potential to deliver the biotech giant a blockbuster hit if the compound can continue to generate positive results in clinical trials. Yet the company is seeking the spotlight on a crowded stage of similar drugs in development from Big Pharma rivals.
Big Pharma betting billions in high-stakes hunt for the next Lipitor
In the wrap-up of the European Society of Cardiology meeting in Munich, Reuters ' Ben Hirschler assessed the field in search of the next potential Lipitors in the pipeline--megablockbusters that will cost hundreds of millions of dollars to test in huge clinical trials--and came up with three big fields. Each of them has big caveats to consider.
Sanofi and Roche race to PhIII with drugs aimed at hot PCSK9 gene
Get ready to see one of hottest areas of cholesterol drug research explode with new studies. Sanofi and partner Regeneron have begun enrollment for late-stage trials to test their drug REGN727 that targets the PCSK9 gene to lower cholesterol. And Roche is fast on their tail with its own Phase III program for a PCSK9 treatment.
Sanofi's Zerhouni rewrites the company playbook on R&D
As Zerhouni tells the story, Sanofi is essentially starting over on the R&D side, picking up the pieces on the translational side of research; figuring out how to take something truly innovative in the lab and turn it into a new product.
Sanofi/Regeneron add to stockpile of promising PCSK9 LDL drug data
Over the long Memorial Day, weekend Regeneron Pharmaceuticals ($REGN) and Sanofi ($SNY) added to their stockpile of promising mid-stage data for their PCSK9 drug, which is designed to slash levels of "bad" LDL-cholesterol.
Alnylam scores efficacy data with PCSK9 drug
The data show that the small company has a horse in the race to advance PCSK9-targeting drugs as a brand new category of treatments for lowering LDL cholesterol.
